# MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

Study · id `cardio:ct-nct03961334` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03961334](<https://clinicaltrials.gov/study/NCT03961334>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03961334

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 620 participants.

## Technical summary

Registry record NCT03961334. Randomized; no masking; primary purpose prevention. Start 2019-12-05 (actual); primary completion 2025-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 620 participants (planned count; ClinicalTrials.gov record NCT03961334, source copy `cardio:ctgov-nct03961334-2023-08-16`, retrieved 2026-10-26)
- Started: 2019-12-05 (actual) (ClinicalTrials.gov record NCT03961334, source copy `cardio:ctgov-nct03961334-2023-08-16`, retrieved 2026-10-26)
- Primary completion: 2025-01-31 (anticipated) (ClinicalTrials.gov record NCT03961334, source copy `cardio:ctgov-nct03961334-2023-08-16`, retrieved 2026-10-26)
- Completion: 2026-01-31 (anticipated) (ClinicalTrials.gov record NCT03961334, source copy `cardio:ctgov-nct03961334-2023-08-16`, retrieved 2026-10-26)
- Countries: Greece; Norway; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT03961334, source copy `cardio:ctgov-nct03961334-2023-08-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03961334-2023-08-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Acronym: MOSES
- Condition: Stroke, Ischemic
- Intervention (Drug): Dabigatran
- Intervention (Drug): Apixaban
- Intervention (Drug): Edoxaban
- Intervention (Drug): Aspirin
- Intervention (Drug): Clopidogrel
- Lead sponsor: University of Zurich
- Lead sponsor class: OTHER
- Collaborator: Swiss National Science Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Dabigatran (`cardio:dabigatran`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: University of Zurich (`cardio:org-university-of-zurich`)
- Registry lists this organization as a collaborator: Swiss National Science Foundation (`cardio:org-swiss-national-science-foundation`)

## Provenance

Content hash: a3d272fbbbe91f105dd8fdec20db1ef62da4d928a0efc3ef73818d8d1a036952
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
